Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (3046)	3/25/1998 10:36:00 PM
From: Doug Shapiro	Read Replies (2) \| Respond to of 7041

I don't think so Brad if you have not read it or even if you have now is a good time to re-read this one. Doug asensio.com

To: Brander who wrote (3046)	3/26/1998 9:01:00 AM
From: Hank	Read Replies (1) \| Respond to of 7041

Thanks for the clarification on the different mechanisms of action. However, I still do not see the patent approval as necessarily significant with regards to an FDA approval. One aspect that I would like your opinion on is the potentially adverse side affects that a general vasodialator would have on somebody who is already on hypertension medication. ED can be caused by alcoholism, smoking, obesity, and, ironically enough, other hypertension medications. Men suffering from one or more of these afflictions often suffer from high blood pressure as well. Don't you see a potential danger in giving a vasodialator to a person who is already on blood pressure medicine?